BRAF and congenital mesoblastic nephroma: Similarly, trametinib significantly improved pain and pruritus in another 4-year-old girl with giant CMN and a CUX1-BRAF fusion mutation after only two weeks of therapy; fading of the lesion was noted after 22 months of treatment [123].